soul trial semaglutide oral cardiovascular outcomes results Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design semaglutide cardiovascular outcomes news today

Challenges in the GLP-1 Obesity Treatment Landscape Access and Affordability: High costs of GLP-1 drugs limit accessibility for many patients

The foremost limitation is the absence of large-scale, randomized, and well-controlled clinical trials capable of establishing definitive evidence of safety and efficacy in human populations

For example, in Section E we showed that moderate oxidative stress causes blood GSH and blood cysteine to rise, but severe oxidative stress causes blood GSH and blood cysteine to fall

Autophagy and metabolism

A large study by Ohno and colleagues, published in Nature in 2020, found that the risk of developing RA rises with every roughly 5 kg of weight gain or every inch added to your waistline

Peer review Peer review information Nature Communications thanks Shigetoshi Sano and the other, anonymous, reviewer(s) for their contribution to the peer review of this work